| Identification | Back Directory | [Name]
LF 1695 | [CAS]
86187-86-2 | [Synonyms]
LF 1695
5-Amino-4'-chloro-2-(4-methyl-1-piperidinyl)benzophenone
[5-Amino-2-(4-methyl-1-piperidinyl)phenyl](4-chlorophenyl)methanone
[2-(4-methyl-1-piperidinyl)-5-aminophenyl]-(4-chlorophenyl)-methanone | [Molecular Formula]
C19H21ClN2O | [MDL Number]
MFCD09838522 | [MOL File]
86187-86-2.mol |
| Hazard Information | Back Directory | [Description]
LF 1695 is a synthetic immunomodulator. | [in vitro]
This was further confirmed by the fact that LF 1695 inhibited the second wave of platelet aggregation induced by ADP as well as arachidonic acid effects. Incubation of platelets with [14C]arachidonic acid in the presence of 60 microM LF 1695 resulted in a strong inhibition of arachidonic acid incorporation into the various cell lipids, indicating that arachidonic acid mobilization might be due to inhibition of reacylation processes._x000D_
_x000D_
Reference: Biochem Pharmacol. 1989 Sep 1;38(17):2763-72. https://pubmed.ncbi.nlm.nih.gov/2505775/ | [in vivo]
CBA, H2k mice receiving a lethal dose of irradiation were injected with spleen cells from LF 1695-treated or untreated C57 Bl/6, H2b mice via different routes. Mice treated intraperitoneally with LF 1695 at 2.5 or 5 mg/kg/day showed an increase of GvHR intensity with splenic index of 1.71 and 1.80, respectively. When the animals were treated continuously through drinking water containing LF 1695 (4 mg/kg, 10 mg/kg or 100 mg/kg), these ratios were: 1.82, 1.10 and 1.37, respectively. Finally, LF 1695 enhanced GvHR significantly when used at low doses, while high doses induced a decrease of GvHR intensity._x000D_
_x000D_
Reference: Int J Immunopharmacol. 1991;13(5):599-604. https://pubmed.ncbi.nlm.nih.gov/1838358/ | [target]
LF 1695 is a synthetic immunomodulator. |
|
|